Recombinant Rabbit T-lymphocyte activation antigen CD86 (CD86)

What is the molecular structure and classification of Recombinant Rabbit CD86?

Recombinant Rabbit CD86 is a type I transmembrane glycoprotein and member of the immunoglobulin superfamily of cell surface receptors. The protein has a molecular weight of approximately 70 kDa . Structurally, it contains an extracellular domain, a transmembrane region, and a cytoplasmic tail. The recombinant protein version typically includes amino acids 23-246 of the rabbit CD86 sequence, as seen in commercial preparations .

For experimental work, recombinant rabbit CD86 is commonly produced with a C-terminal 6×His tag to facilitate purification and detection . The protein sequence contains multiple immunoglobulin-like domains in its extracellular portion, which are critical for its interactions with binding partners CD28 and CTLA-4.

Methodology note: When selecting recombinant CD86 for experiments, consider whether the expression system (typically mammalian HEK293 cells) and the protein purity (generally >95% by SDS-PAGE with endotoxin levels <1 EU/μg) meet your experimental requirements .

How is CD86 expression regulated in different immune cells?

CD86 shows distinctive expression patterns across immune cell populations. It is expressed at high levels on resting peripheral monocytes and dendritic cells, while maintaining very low density on resting B and T lymphocytes . Expression studies have also identified CD86 on approximately 6% of NK cells, while CD80 (the related costimulatory molecule) is present on fewer than 1% of NK cells .

The regulation of CD86 expression follows specific temporal dynamics. B cell-specific stimuli rapidly upregulate CD86 expression, with peak expression occurring between 18 to 42 hours post-stimulation . This rapid kinetics of induction distinguishes CD86 from other costimulatory molecules and positions it as the major CD28 ligand expressed early in the immune response.

Methodology note: When designing experiments to analyze CD86 expression, time course studies should consider these temporal dynamics. Flow cytometry with anti-CD86 antibodies (such as clone C86/2160R) remains the gold standard for detecting CD86 expression on different cell populations .

What distinguishes CD86 function from that of CD80?

While CD80 and CD86 share structural similarities and binding partners (CD28 and CTLA-4), they exhibit important functional differences:

• Expression kinetics: CD86 shows rapid upregulation following immune activation, while CD80 expression occurs later in the immune response .

• T cell activation potency: CD80 and CD86 demonstrate differential abilities to costimulate T cells based on their activation state. CD86 has been shown to be "substantially inferior in costimulating alloresponses by separated memory T cells, and completely incompetent in costimulating three human T cell clones" .

• Inhibitory potential: Research has demonstrated that CD86 can actively inhibit T cell responses under certain conditions. In experiments with CD80/CD86 double transfectants, the addition of anti-CD86 antibody increased T cell response, suggesting that CD86 was actively inhibitory rather than merely neutral .

• CTLA-4 interaction dominance: When CD86 interacts with CTLA-4, this inhibitory signal may override its stimulatory effects through CD28. Studies show that "addition of anti-CTLA-4 Fab to cultures of HLA-DR1 transfectants co-expressing CD86, fully restored the proliferative response" .

Methodology note: When investigating the differential roles of CD80 versus CD86, blocking antibodies and recombinant CTLA4Ig can be valuable tools to dissect their specific contributions to immune responses.

How does CD86 function in NK cell activation mechanisms?

Recent research has uncovered an unexpected role for CD86 as an activation receptor for NK cell cytotoxicity. While traditionally viewed primarily as a T cell costimulatory molecule, CD86 has been shown to enhance NK cell tumor-killing abilities:

• Direct activation potential: Anti-CD86 antibody stimulation, when properly crosslinked, can enhance NK cell cytotoxicity against tumor targets .

• CTLA4Ig-mediated activation: When CTLA4Ig (a fusion protein containing the extracellular domain of CTLA-4) binds to CD86 on NK cells, it can significantly enhance NK cell cytotoxicity against K562 tumor cells .

• Competition experiments: Research has demonstrated that when anti-CD86 antibody is added together with CTLA4Ig to NK cell cultures, the CTLA4Ig-mediated NK cell activation is partially blocked. If the anti-CD86 antibody is added 2 hours earlier than CTLA4Ig (pre-occupying CD86 molecules), the CTLA4Ig-mediated enhancement of cytotoxicity is completely abolished .

Methodological approach: To investigate CD86's role in NK cell function, researchers should consider:

• NK cell isolation using negative selection methods to preserve receptor expression

• Cytotoxicity assays using 51Cr-release or flow cytometry-based methods

• Blocking experiments with anti-CD86 antibodies and CTLA4Ig with proper timing controls

• Analysis of intracellular signaling pathways activated by CD86 engagement

What signaling pathways does CD86 activate in immune cells?

CD86 engagement initiates several intracellular signaling cascades that contribute to its immunoregulatory functions:

• NF-κB signaling pathway: Upon CD40 engagement, CD86 activates the NF-κB signaling pathway through phospholipase C and protein kinase C activation . This pathway is critical for numerous immune functions including cytokine production and cell survival.

• T cell activation pathways: CD86 interaction with CD28 on T cells contributes to interleukin-2 production and proliferation signaling . This forms part of the critical "signal 2" in the two-signal model of T cell activation.

• Regulatory pathways: CD86 also participates in regulatory pathways through its interaction with CTLA-4, which can deliver inhibitory signals to both the T cell and potentially back to the CD86-expressing cell.

• B cell signaling: CD86 is involved in the regulation of B cell function and plays a role in regulating the level of IgG(1) produced, suggesting its involvement in antibody class switching mechanisms .

Methodological approach: For investigating CD86 signaling pathways, researchers should consider:

• Western blotting for phosphorylated signaling proteins

• Reporter assays for transcription factor activation (particularly NF-κB)

• Calcium flux assays following CD86 engagement

• Inhibitor studies to determine pathway dependencies

How can CD86 function be manipulated for immunotherapeutic applications?

Understanding CD86's roles in immune regulation provides several potential therapeutic applications:

• Enhancing anti-tumor immunity: Since CD86 plays a role in NK cell cytotoxicity, strategies to enhance this function could improve anti-tumor responses . Recombinant proteins or antibodies that engage CD86 in a manner that promotes its activating functions could potentially enhance anti-tumor immunity.

• Modulating autoimmunity: The distinct effects of CD86-mediated costimulation on resting versus activated T cells suggest potential applications in managing autoimmune conditions . Selective targeting of CD86 interactions could help restore immune balance.

• Improving vaccine efficacy: As CD86 is crucial for early T cell activation, incorporating CD86-enhancing strategies into vaccine platforms might improve immune responses, particularly in settings of immune suppression.

Methodological approach: For therapeutic development targeting CD86:

• Structure-based design of selective modulators (agonists or antagonists)

• In vitro screening using functional assays (T cell proliferation, cytokine production)

• Validation in appropriate animal models with humanized immune components

• Consideration of combination approaches targeting both CD80 and CD86 pathways

What are optimal conditions for expression and purification of recombinant rabbit CD86?

Based on established protocols for producing high-quality recombinant rabbit CD86:

Expression system selection:

• Mammalian expression systems (particularly HEK293 cells) are preferred for generating properly folded and glycosylated CD86 .

• The expression construct typically includes amino acids 23-246 of rabbit CD86 sequence, representing the extracellular domain .

• A C-terminal 6×His tag facilitates purification while minimizing interference with the protein's functional domains .

Purification protocol:

• Collect culture supernatant from transfected cells (typically 48-72 hours post-transfection)

• Clarify by centrifugation and filtration through a 0.2 μm filter

• Purify using Ni-NTA affinity chromatography

• Consider additional purification steps (ion exchange, size exclusion) if higher purity is required

• Validate purity by SDS-PAGE (should be >95%)

• Confirm endotoxin levels are below 1 EU/μg using LAL method

• Lyophilize from a 0.2 μm filtered solution of PBS, pH 7.4

Quality control metrics:

• Purity: >95% by SDS-PAGE

• Endotoxin: <1 EU/μg

• Functionality: Binding to recombinant CD28 and CTLA-4 by ELISA

• Proper folding: Circular dichroism spectrometry

What methods are most effective for studying CD86-mediated immune cell activation?

When investigating CD86's immunoregulatory functions, several methodological approaches yield robust and reproducible results:

For T cell activation studies:

• Mixed lymphocyte reactions (MLR): Compare costimulation potency using antigen-presenting cells expressing CD86 alone, CD80 alone, or both molecules .

• Artificial APC systems: Transfect cell lines with MHC molecules and CD86 to create standardized stimulator cells.

• Blocking studies: Use anti-CD86 antibodies (e.g., clone C86/6500R) to block CD86-mediated costimulation .

• Recombinant protein stimulation: Plate-bound or bead-coupled recombinant CD86 protein can stimulate T cells in the presence of TCR engagement.

For NK cell activation studies:

• Cytotoxicity assays: Use standard K562 targets with 51Cr-release or flow cytometry-based killing assays .

• Antibody stimulation: Anti-CD86 antibodies with proper crosslinking can stimulate NK function .

• CTLA4Ig engagement: CTLA4Ig can bind CD86 on NK cells and enhance cytotoxicity .

• Competition experiments: Pre-incubation with anti-CD86 antibodies can block CTLA4Ig-mediated NK cell activation .

Readout measurements:

• Proliferation (³H-thymidine incorporation or CFSE dilution)

• Cytokine production (ELISA or intracellular cytokine staining)

• Activation marker expression (flow cytometry)

• Cytotoxicity (51Cr-release or flow-based killing assays)

How should researchers design experiments to differentiate CD86 versus CD80 functions?

Given the overlapping but distinct functions of CD86 and CD80, careful experimental design is crucial:

Expression system considerations:

• Create matched expression systems with equivalent levels of CD80, CD86, or both molecules

• Use inducible expression systems to control timing and magnitude of expression

• Consider species matching between the costimulatory molecules and responding cells

Functional comparison approaches:

• Kinetic studies: Examine different time points to capture the distinct temporal dynamics of CD80 versus CD86 responses .

• Cell type specificity: Test responses across naive T cells, memory T cells, and T cell clones, where differential effects are most pronounced .

• Receptor blocking strategies: Use selective antibodies against CD28 or CTLA-4 to dissect which receptor interaction dominates for each costimulatory molecule .

• Competition experiments: In CD80/CD86 double-expressing systems, selectively block each molecule to determine their relative contributions .

Data interpretation table for CD80 vs CD86 functional assays:

How can researchers overcome challenges in detecting low CD86 expression?

CD86 expression can be challenging to detect in certain cell types or conditions, particularly in resting lymphocytes. Here are methodological approaches to overcome these challenges:

Enhancing detection sensitivity:

• Signal amplification: Use biotin-streptavidin systems or tyramide signal amplification for immunohistochemistry

• High-sensitivity flow cytometry: Utilize fluorophores with high quantum yield (PE, APC) rather than lower-brightness options (FITC)

• Pre-enrichment strategies: Magnetic or flow-based enrichment of cell populations of interest prior to analysis

• Recombinant antibody selection: Choose high-affinity recombinant antibodies such as rabbit monoclonal clone C86/2160R or C86/6500R

Experimental design considerations:

• Include positive controls (stimulated B cells or dendritic cells) in each experiment

• Establish proper gating strategies based on fluorescence-minus-one (FMO) controls

• Consider time points carefully, as CD86 expression peaks between 18-42 hours after B cell stimulation

• When studying NK cells, be aware that only approximately 6% express CD86 under normal conditions

Troubleshooting low signal:

• If signal is poor, check antibody concentration (optimal range for IHC-P: 1-2 μg/ml )

• Test multiple antibody clones, as epitope accessibility may differ between applications

• For fixed samples, optimize fixation time and antigen retrieval methods

• Consider fresh vs. frozen sample preparation differences

What are common pitfalls in CD86 functional studies and how can they be avoided?

Several experimental challenges can complicate CD86 functional studies. Here are key pitfalls and their solutions:

Challenge: Conflicting results between CD86 stimulation studies

• Cause: CD86 can have different effects depending on whether cells express CD28, CTLA-4, or both

• Solution: Characterize receptor expression on target cells before functional studies

• Method: Flow cytometry analysis of CD28 and CTLA-4 expression before stimulation experiments

Challenge: CD86 antibodies fail to stimulate expected responses

• Cause: Many antibodies cannot properly crosslink CD86 on their own

• Solution: Use secondary crosslinking antibodies or plate-bound primary antibodies

• Method: Pre-coat plates with anti-CD86 or use secondary anti-Fc antibodies for crosslinking

Challenge: Difficulty distinguishing CD86-specific vs. general costimulatory effects

• Cause: Multiple costimulatory pathways often operate simultaneously

• Solution: Use selective blocking approaches and genetic models (knockout/knockdown)

• Method: Combine anti-CD86 with blockers of other pathways (anti-CD80, anti-OX40, etc.)

Challenge: Variability in recombinant CD86 protein functionality

• Cause: Protein quality, glycosylation differences, tag interference

• Solution: Validate each protein lot with functional binding assays

• Method: ELISA-based binding assays to recombinant CD28 and CTLA-4

Challenge: Species differences confound interpretation

• Cause: CD86 function may differ between human, mouse, and rabbit systems

• Solution: Use species-matched components when possible

• Method: When using rabbit CD86, pair with rabbit T cells or validated cross-reactive systems

How should researchers interpret seemingly contradictory data about CD86 function?

The literature contains apparent contradictions about CD86 function, stemming from context-dependent effects. Here's a framework for interpretation:

Key contextual factors affecting CD86 function:

• Target cell activation state: CD86 has "distinct effects on resting versus activated T cells" . While it effectively costimulates naive T cells, it can be inhibitory for memory T cells and some T cell clones.

• Receptor balance: The ratio of CD28 to CTLA-4 expression on target cells determines whether CD86 engagement produces net stimulation or inhibition. Evidence shows "CTLA-4 ligation may dominate the outcome of CD86-mediated costimulation of activated CD4+ T cells" .

• Temporal considerations: CD86 functions differently at early versus late stages of immune responses due to changing receptor expression patterns and cellular differentiation states.

• Cell type specificity: CD86 functions differently on different immune cell types:

  • On APCs: Primarily delivers costimulatory signals to T cells

  • On NK cells: Acts as an activation receptor for cytotoxicity

  • On B cells: Regulates IgG(1) production

Interpretative framework for contradictory data:

Methodological recommendation: When publishing apparently contradictory findings, perform comprehensive phenotyping of all cell populations and clearly report receptor expression patterns, activation states, and temporal aspects of the experimental system.

What are promising research avenues for expanding our understanding of CD86 biology?

Several areas represent particularly promising directions for advancing CD86 research:

Structural biology approaches:

• High-resolution structural analysis of CD86-CD28 and CD86-CTLA-4 complexes

• Structure-based design of selective modulators that can bias toward stimulatory or inhibitory functions

• Investigation of CD86 conformational changes upon receptor binding

Single-cell analysis:

• Single-cell transcriptomics to identify cell subsets with differential CD86 responsiveness

• Spatial transcriptomics to understand CD86 signaling in tissue microenvironments

• Temporal single-cell profiling during immune responses to map CD86 dynamics

Therapeutic applications:

• Development of CD86-targeted approaches for cancer immunotherapy, particularly leveraging its role in NK cell activation

• Exploration of CD86 modulation for autoimmune disease treatment

• Investigation of CD86 polymorphisms and their impact on disease susceptibility

Methodological innovations needed:

• Improved reporter systems for tracking CD86 signaling in real-time

• Development of conditional knockout models to study cell type-specific CD86 functions

• Advanced imaging techniques to visualize CD86-receptor interactions at the immunological synapse